The Anti-CD38 Reference Antibody (felzartamab) is developed as a reference standard for research and development of biological products, particularly in the development of antibodies targeting the CD38 protein, which is highly expressed in malignant plasma cells such as those in multiple myeloma.

It is used in quality control of manufacturing processes, such as assessing purity, stability, and activity of other developing target antibodies. Additionally, it supports comparability studies to ensure that drug batches exhibit consistent biological properties.

In basic research, this antibody aids in understanding the role of CD38 in immune cell signaling and apoptosis mechanisms, which is crucial for discovering new therapies for autoimmune disorders and CD38-positive hematologic malignancies.